BioCryst Pharmaceuticals BCRX – Swine Flu Stocks To Watch

BioCryst Pharmaceuticals Swine Flu (NASDAQ: BCRX)

With two forms of influenza vaccine, BioCryst Pharma has the potential to emerge as one of the world’s top biotech companies in the fight against the swine flu.

Peramivir, one of their influenza flu vaccines, is currently going through the clinical trials to treat life threatening strains including the H1N1 virus that causes the swine flu and the H5N1 virus that causes the bird flu.

BioCryst Peramivir is the most advanced antiviral drug of its kind, and would provide an influenza treatment option for patients whom the current oral or inhaled medications (Tamiflu, Relenza or Fluzone) are not appropriate.

Other top biotech companies involved in the development of influenza treatments include AVI Biopharma (AVII), and Sinovac Biotech (SVA) but only one has exceeded the 450% performance we have seen on BioCryst stock price since the first swine flu symptoms were reported in Mexico: Novavax NVAX.

BioCryst Pharmaceuticals Inc. Company Overview

With a strong intellectual property position and multiple products in development Biocryst Pharmaceuticals has focused its business strategy to increase the value of their drug candidate portfolio by retaining drug product rights.

BioCryst Pharma is also developing strategic alliances with top companies like Shionogi & Co Ltd., a top pharmaceutical company from Japan.

Their primary focus is product development efforts on cancer, autoimmune diseases, and viral infections such as the swine flu; all large and further emerging markets.